We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| African Pioneer Plc | ASP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.75 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.75 |
| Top Posts |
|---|
Posted at 03/2/2007 12:55 by gac100 Probably nothing in it, and nothing to worry about for Ascribe investors, but I've sold my holding, being uncomfortable with the following:"the FT established that the three houses in Oxfordshire and Warwickshire searched by the SFO belonged to Chris Moore, who stepped aside as Torex Retail chairman on Wednesday, Rob Loosemore, the company's former executive chairman, and Mark Woodbridge, a close associate of Mr Moore." Chris Moore and Mark Woodbridge were appointed non-executive directors of Ascribe in May 2005. Moore resigned in Dec 2005. His resignation was announced in Oct; Ascribe implied that he had a lot on his plate with Torex "recently appointed executive chairman of Torex Retail plc", although he would "remain a strategic consultant to [Ascribe]." Moore sold his 10,822,771 Ascribe shares in Feb 2006 "in response to institutional investor demand" (Artemis increased its stake in Ascribe at the same time). Woodbridge, as far as I know, is still a non-executive director of Ascribe and was chairman of the company's Audit Committee for the year ending 6 Jun 2006 (Annual Report). On the same day that Moore and Woodbridge were appointed to the Ascribe Board (in May 2005), the company was "pleased to announce both the appointment of Evolution Securities Limited as their new nominated adviser, broker and financial adviser and Citigate Dewe Rogerson as their financial public relations adviser with immediate affect." Evolution and Citigate also represent Torex. (although Ascribe later Aug 2006 appointed Cenkos Securities its nominated adviser and broker). On the same day Moore's intention to resign as non-executive director of Ascribe was announced (in Oct 2005), the company appointed Graham Lewis as Chief Executive. Lewis lasted less than a year. Lewis's intention to resign was announced at the end of Jun 2006 and he resigned at the end of July, 6 weeks before Ascribe announced its final results for the year ended 30 Jun. His resignation was "Due to personal circumstances" and passed with very little ceremony (the announcement was made in an "Acquisition" RNS). Ascribe has made a good number of acquisitions over the past couple of years. There is speculation that Torex's problems may be connected with how the company dealt with acquisitions and contracts in its books (cf. ISoft). Moore and /or Woodbridge non-exec directors with Ascribe remember probably had no input at all into how Ascribe did its accounts, but I have no way of knowing. Finally, as already mentioned Artemis is a major institutional shareholder in Ascribe, and was buying when Moore was selling. It was been alleged that Artemis sold its entire holding in Torex before the sh*t hit the fan there. Artemis's stake in Ascribe was a very marginal factor in my decision, and is probably of more interest to Torex investors than Ascribe investors. I repeat there may well be nothing to worry about for ASP investors. I'm very, very cautious by nature. |
Posted at 18/9/2006 07:43 by currypasty Buy Ascribe at 36p A tip from Techinvest Newsletter Back in 2001, The Audit Commission published a report entitled "A Spoonful of Sugar". In this it said there was potentially up to 1,200 lives and 500 million pounds a year that could be saved by UK hospitals if they used clinical information systems to reduce patient medication errors. Similar such reports in the US showed that the problem certainly wasn't localised in the UK . In 2004, another study issued by Liverpool University said that UK citizens were more likely to die from a "medical misadventure" than from a road traffic accident. Fairly sobering reading which the Government took to heart. It has since issued hospitals with targets to reduce the number of medication errors that occur. As a result, demand for clinical management systems has boomed. This is an area that Ascribe has focused on since it was established back 1984 (then called ASC Computer Software) by Chairman and Pharmacist Stephen Critchlow and Dr Chris Jones. They originally developed software to overcome the difficulties they were having handling clinical information while working for the NHS. The Company was floated on AIM in December 2004 in order to raise funds to acquire Protechnic Exeter, a health IT Company which supplied primary care trusts and GPs with community and child health systems. Since then, Ascribe has gone from strength to strength, which hasn't been adequately reflected in the share price - 32p compared with an IPO price of 18p. Recent weakness in the stock market has given subscribers a chance to get on board. *This email represents the views of UK-Analyst and are not the views of IG Index. Remember that spread betting is a leveraged product and can result in losses that exceed your initial deposit. It may not be suitable for everyone, so please ensure that you fully understand the risks involved. The value of investments can go down as well as up. Investing in equities can lose you part or all of your capital. Smaller company shares can be relatively illiquid and thus hard to trade. And that makes such investments more of a high risk than larger company shares. UK-Analyst.com is owned by t1ps.com which is authorised and regulated by the FSA and can be contacted at 49 Rivington St, London EC2A 3QB or on 0207 033 9389. A January 2002 Silicon Bridge Research report estimated that over 40% of the UK Secondary Care market used an Ascribe system, making it the then largest supplier of pharmacy software. Since then, Ascribe has won over 90% of the public tenders it has competed for in the UK . It has also sold systems in Australia , New Zealand , Malaysia and Hong Kong . Originally there were four main Ascribe products, which could be used alone or in combination to provide an appropriate medicines management solution: Pharmacy, used to assist hospital pharmacies to dispense medicine and includes stock control, labelling, drug level monitoring and drug utilisation reporting; Electronic Prescribing, used by doctors to send prescriptions directly to dispensing pharmacies; Clinical Decision Support, used by medical staff to check prescriptions with reference to the condition of a particular patient; Integrated Clinical Workstation, a system capable of integrating legacy systems to offer clinicians a single clinical view, a solution suggested in The Audit Commission report. Ascribe floated on AIM to finance its first acquisition, but it certainly hasn't stopped there. In the intervening period it has completed a further six, taking it into complementary areas while at the same time enhancing earnings. In May 2005 it moved into A&E when it acquired Footman Walker, a leading supplier of A&E information systems in the UK with a 30% market share. A month later, Ascribe took over Park Systems, the largest independent supplier of retail pharmacy computer systems in the UK . At the same time it bought Archive, a supplier of software to Protechnic Exeter. Barwick Systems was added in March this year. It supplies Patient Administration Systems (PAS) to NHS hospitals. Many also use Ascribe's Pharmacy or A&E systems. In May, Ascribe broadened its geographic reach acquiring the health division of private New Zealand-company Jade Software. This gave it greater expertise in mental health and more Australasian sales: Jade provides IT solutions to 24 hospitals and health organisations. A month later Ascribe acquired HE Information Systems (HEIS), another supplier of PAS to 21 NHS hospitals for up to 6.5 million pounds. As with Barwick Systems, many of HEIS's clients also use Ascribe's Pharmacy or A&E systems. In the year ended 31 March 2005 , HEIS made a pre-tax profit of 0.52 million pounds from turnover of 2.5 million pounds and will enhance earnings in its first year of ownership. A record result was achieved for the year ended June 30 as sales surged 85% to 9.9 million pounds. The three recent acquisitions contributed 0.93 million pounds. Recurring maintenance revenue accounted for 62% of sales. Profit before tax and goodwill amortisation was 2 million pounds, compared with 0.8 million pounds last time. This gave earnings per share of 1.59p (0.64p). Cash inflow from operations was 2.4 million pounds, which easily covering reported operating profit. Net debt after the acquisitions was 0.52 million pounds. With sales underpinned by the high proportion of recurring revenue, Ascribe is a high growth stock with little downside risk. Two directors gave a vote of confidence in June when they added to their holdings. Follow their lead. Buy. Techinvest is the one of the few investment newsletters with years of experience in successfully helping investors make money from the tech sector of the London Stockmarket. |
Posted at 09/11/2005 14:04 by ltinvestor I thought that you were a long term investor! |
Posted at 30/9/2005 15:01 by currypasty half a page spread in Investors chronical today, BUY ! |
Posted at 18/7/2005 09:03 by barnsey We tipped shares in XN Checkout at 280p in March when we reckoned that, despite their excellent run, it was still not too late take part in a remarkable recovery story. XN, which supplies cash till technology to the leisure sector, is now on the receiving end of a takeover bid from an acquisitive rival, Torex Retail. Eyebrows were raised when the Torex offer valued XN at just 265p a share.Disappointed shareholders thought they had been short-changed and noted that XN's non-executive chairman, Chris Moore, is also chief executive of Torex Retail and a major shareholder in XN. Such concern has subsided. Because the offer is in the form of Torex shares, XN's fortunes are now tied to those of the bidder, and XN's shares now trade at 290p. This looks like a done deal as Torex already has acceptances from holders of 38.5% of XN's shares. From the Financial Mail on sunday For your information, i do not hold. Investors meet on July 27 to approve the takeover, with the first closing date for acceptances two days later. By coincidence, Moore was recently appointed non-executive chairman of Ascribe, a software company specialising in medicine management and another recent Midas selection. Tipped at 27½p, the shares are now worth 32p. Torex is very much on the acquisition trail, but surely lightning won't strike twice with a bid for Ascribe? C |
Posted at 11/9/2003 16:56 by hugepants JJ - Around 65% which is pretty darned good for 10 months. As to whats happening - Can Damian Aspinall buy shares in the open market even having made the offer? If he can then perhaps he's being clever. Offer 0.17p initially, knowing hes taking the pish, then put in a big buy order that allows investors to sell at 0.18p. The psychology is that investors will think the 0.18p is a great deal! Alternatively its some other guy buying cheap cash (DA's offer is now pants) knowing DA will have to put in a higher offer to avoid having a pesky large shareholder on the register. So will DA now up his offer to say 0.2p a share? Lets face facts here people, the current offer is redundant if people can sell out at 0.18p. |
Posted at 11/9/2003 14:55 by hugepants I reckon someones noticed the big discount to cash and put in a mammoth (OK relatively speaking!) buy order. He knows it will be filled at 0.18p because most investors will look at anything above 0.17p as a bonus. |
Posted at 16/4/2003 21:44 by alwaysbroke John - leave Donna alone for 5 minutes and put your energy back into this stock.An announcement is overdue!!! Don't neglect your investors or they will be wishing you many very dirty nappies. |
Posted at 07/12/2002 13:45 by barts Could this also be something to do with the rise?Sydney, Oct. 15 (Bloomberg) -- Publishing and Broadcasting Ltd., controlled by billionaire Kerry Packer, is seeking casinos it could buy in the U.K. on expectations a review of gaming regulations could help make British gambling businesses more profitable. The owner of Crown casino, Australia's largest, may spend as much as A$1.5 billion ($760 million) on a U.K. purchase, the Sydney Morning Herald reported, without naming sources. Its interest was spurred by the July release of the U.K. Gambling Review Body report, headed by Sir Alan Budd, which recommended easing the nation's 30-year-old gambling restrictions. ``This is a very preliminary investigation into potential opportunities that might exist in the U.K. after the report,'' said Sara Clifton, a PBL spokeswoman. Crown is PBL's biggest source of revenue, accounting for about 43 percent of sales last fiscal year, eclipsing sales from its Nine Network, Australia's highest-rating television network, and magazines such as Australian Women's Weekly. Better-than- expected sales at Crown may also encourage Packer, himself a keen gambler, to expand the business, analysts said. ``We like the idea of companies testing their mettle in overseas markets,'' said Hans Kunnen, who helps manage A$18 billion ($9.1 billion) at Colonial First State Investments in Sydney. ``It doesn't do (PBL) any harm to explore the possibilities.'' Opportunities The Gambling Review Body was set up in November 1999 to bolster competition in the U.K.'s 42 billion pound ($61 billion)-a- year industry. It also reviewed the 1968 Gambling Act to help companies compete with the National Lottery and cope with competition from overseas and Internet-based rivals offering lower- tax, or tax-free, bets. Crown's ``strong management would be easily exportable overseas,'' PBL's Clifton said. The Sydney-based television, gaming and publishing company wants to expand offshore to find growth, which is limited in Australia by the island nation's relatively small population of 19 million. PBL fell 30 cents, or 3.2 percent, to A$9.00. Analysts said the decline tracked falls in other media stocks. The ASX Media Index fell 2.8 percent today. PBL shares have fallen 29 percent this year. PBL executives ``wouldn't be doing their job if they weren't looking,'' said Mike Mangan, an analyst at Deutsche Bank AG. He wouldn't speculate on possible takeover targets. Among U.K. gambling and casino stocks, Stanley Leisure Plc has a market value of 316 million pounds ($459 million) and last traded at a price 14.7 times its estimated earnings -- less than the 19 times estimated earnings that PBL trades at. Aspinalls Online Plc has a market value of 19.7 million pounds and Gaming Insight Plc has a market value of 18.2 million pounds. Robert Gee, a Perth-based gaming analyst at CIBC World Markets, said if PBL can't find suitable acquisitions in the U.K., it might build casinos in that market to take advantage of new laws. When another Packer-managed company, CPH Investment Corp., in July sold its 15 percent of John Fairfax Holdings Ltd., Australia's biggest newspaper publisher, for A$436 million, analysts and investors speculated he might buy Australian gaming businesses, such as Jupiters Ltd. or Burswood Ltd. ``A diversified earnings stream is not a bad thing in this or any other environment,'' Kunnen said. The Gambling Review Body report recommended increasing the number of poker machines allowed in U.K. casinos to eight per table, the newspaper reported. Casinos would be allowed to offer sports betting, bingo and live entertainment. PBL dismissed speculation the company was interested in buying London Clubs International Plc., the Morning Herald said, without naming anyone. |
Posted at 04/10/2002 11:40 by robandkerry Its true Terry, the only people that have pushed the price up, is the investors on this thread. You need a new thread Jason trust me. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
